Amgen (AMGN) 10-Q 27 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 20, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Amgen Inc.
Entity Central Index Key	318154
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		760,323,664

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income (Unaudited) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Product sales	$4,874	$4,356
Other revenues	159	165
Total revenues	5,033	4,521
Operating expenses:
Cost of sales	1,033	1,090
Research and development	894	1,027
Selling, general and administrative	1,026	1,023
Other	58	17
Total operating expenses	3,011	3,157
Operating income	2,022	1,364
Interest expense, net	252	259
Interest and other income, net	106	99
Income before income taxes	1,876	1,204
Provision for income taxes	253	131
Net income	$1,623	$1,073
Earnings per share:
Basic (in usd per share)	$2.13	$1.42
Diluted (in usd per share)	$2.11	$1.40
Shares used in calculation of earnings per share:
Basic (in shares)	761	757
Diluted (in shares)	770	768
Dividends paid per share (in usd per share)	$0.79	$0.61

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (Unaudited) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income	$1,623	$1,073
Other comprehensive income (loss), net of reclassification adjustments and taxes:
Foreign currency translation losses	-173	-8
Effective portion of cash flow hedges	178	2
Net unrealized gains on available-for-sale securities	140	40
Other	0	1
Other comprehensive income, net of tax	145	35
Comprehensive income	$1,768	$1,108

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Current assets:
Cash and cash equivalents	$2,864	$3,731
Marketable securities	24,254	23,295
Trade receivables, net	2,548	2,546
Inventories	2,686	2,647
Other current assets	2,712	2,494
Total current assets	35,064	34,713
Property, plant and equipment, net	5,123	5,223
Intangible assets, net	12,265	12,693
Goodwill	14,721	14,788
Other assets	1,779	1,592
Total assets	68,952	69,009
Current liabilities:
Accounts payable	888	1,212
Accrued liabilities	4,948	5,296
Current portion of long-term debt	500	500
Total current liabilities	6,336	7,008
Long-term debt	29,841	30,215
Long-term deferred tax liability	3,330	3,461
Other noncurrent liabilities	2,939	2,547
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding - 760.4 shares in 2015 and 760.4 shares in 2014	30,420	30,410
Accumulated deficit	-4,051	-4,624
Accumulated other comprehensive gain/(loss)	137	-8
Total stockholders’ equity	26,506	25,778
Total liabilities and stockholders’ equity	$68,952	$69,009

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock and additional paid-in capital, par value (in usd per share)	$0.00	$0.00
Common stock and additional paid-in capital, shares authorized	2,750,000,000	2,750,000,000
Common stock and additional paid-in capital, shares outstanding	760,400,000	760,400,000

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$1,623	$1,073
Depreciation and amortization	524	518
Stock-based compensation expense	70	87
Other items, net	-241	-8
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net	-9	180
Inventories	51	-3
Other assets	-139	-181
Accounts payable	-312	92
Accrued income taxes	85	-48
Other liabilities	-323	-568
Net cash provided by operating activities	1,329	1,142
Cash flows from investing activities:
Purchases of property, plant and equipment	-118	-172
Cash paid for acquisitions, net of cash acquired	0	-104
Purchases of marketable securities	-6,931	-2,884
Proceeds from sales of marketable securities	4,999	1,811
Proceeds from maturities of marketable securities	1,201	957
Change in restricted investments	0	-329
Other	-103	-44
Net cash used in investing activities	-952	-765
Cash flows from financing activities:
Repayment of debt	-125	-125
Repurchases of common stock	-464	0
Dividends paid	-599	-460
Net proceeds from issuance of common stock in connection with the Company’s equity award programs	18	38
Settlement of contingent consideration obligation	-225	0
Other	151	52
Net cash used in financing activities	-1,244	-495
Decrease in cash and cash equivalents	-867	-118
Cash and cash equivalents at beginning of period	3,731	3,805
Cash and cash equivalents at end of period	$2,864	$3,687

Summary_of_significant_account

Summary of significant accounting policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies
	Business
	Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
	Basis of presentation
	The financial information for the three months ended March 31, 2015 and 2014, is unaudited but includes all adjustments (consisting of only normal recurring adjustments, unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
	The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2014.
	Principles of consolidation
	The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
	Use of estimates
	The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
	Property, plant and equipment, net
	Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $7.2 billion and $7.0 billion as of March 31, 2015, and December 31, 2014, respectively.
	Recent accounting pronouncements
	In May 2014, a new accounting standard was issued that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. This new standard will be effective for interim and annual periods beginning January 1, 2017, and is required to be adopted using either a full retrospective or a modified retrospective approach, and early adoption is not permitted. We are currently evaluating the impact that this new standard will have on our financial statements.
	In April 2015, a new accounting standard was issued that amends the presentation for debt issuance costs. Upon adoption, such costs shall be presented on our consolidated balance sheets as a direct deduction from the carrying amount of the related debt liability and not as a deferred charge presented in Other assets on our consolidated balance sheets. This new standard will be effective for interim and annual periods beginning on January 1, 2016, and is required to be retrospectively adopted. Adoption of this new standard is not expected to have a material impact on our consolidated balance sheets or related disclosures.

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring
	During the second half of 2014, we initiated a restructuring plan to invest in continuing innovation and the launch of our new pipeline molecules, while improving our cost structure. As part of the plan, we stated that we would reduce our staff by 3,500 to 4,000 by the end of 2015, close our facilities in Washington state and Colorado and reduce the number of buildings at our headquarters in Thousand Oaks, California.
	We continue to estimate that $935 million to $1,035 million of pre-tax restructuring charges will be incurred in connection with the implementation of our restructuring plan, of which $650 million has been incurred through March 31, 2015. Included in these amounts are: (i) separation costs of $535 million to $585 million with respect to the staff reductions, and (ii) asset-related charges of $400 million to $450 million consisting primarily of asset impairments, accelerated depreciation and other related costs resulting from the consolidation of our worldwide facilities.
	During the three months ended March 31, 2015, we incurred $92 million of restructuring costs. We expect that substantially all remaining restructuring actions and related estimated costs, as discussed above, will be incurred during the remainder of 2015 to support our ongoing transformation and process improvement efforts.
	The following table summarizes the charges recorded related to the restructuring plan by type of activity and the locations recognized within the Condensed Consolidated Statement of Income (in millions):
			During the three months ended March 31, 2015
			Separation costs			Asset impairments			Accelerated depreciation		Other		Total
	Cost of sales		$	—		$	—		$	13	$	1	$	14
	Research and development		—			—			14		3		17
	Selling, general and administrative		—			—			1		3		4
	Other		48			—			—		9		57
	Total		$	48		$	—		$	28	$	16	$	92
	Asset impairment and accelerated depreciation charges were recognized in connection with our decision to exit Boulder and Longmont, Colorado, Bothell and Seattle, Washington and the consolidation of facilities in Thousand Oaks, California. The decision to accelerate the closure of these manufacturing and research and development (R&D) facilities was principally based on optimizing the utilization of our sites in the United States, which includes an expansion of our presence in the key U.S. biotechnology hubs of South San Francisco, California and Cambridge, Massachusetts.
	The following table summarizes the charges and spending related to the restructuring plan (in millions):
		During the three months ended March 31, 2015
		Separation costs			Other			Total
	Restructuring liabilities as of December 31, 2014	$	221		$	23		$	244
	Expense	48			9			57
	Payments	(99		)	(10		)	(109		)
	Restructuring liabilities as of March 31, 2015	$	170		$	22		$	192

Income_taxes

Income taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income taxes	Income taxes
	The effective tax rate for the three months ended March 31, 2015, was 13.5% compared with 10.9% for the corresponding period of the prior year. The effective rates are different from the federal statutory rates primarily as a result of indefinitely reinvested earnings of our foreign operations. We do not provide for U.S. income taxes on undistributed earnings of our foreign operations that are intended to be invested indefinitely outside of the United States. In addition, the effective tax rates for both periods were reduced by foreign tax credits associated with the Puerto Rico excise tax described below.
	The increase in our effective tax rate for the three months ended March 31, 2015, was due primarily to the unfavorable tax impact of changes in the jurisdictional mix of income and expenses, offset partially by a state tax audit settlement in the three months ended March 31, 2015.
	Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturing subsidiary in Puerto Rico. The rate is 4.0% effective July 1, 2013 through December 31, 2017. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred.
	One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely audited by the tax authorities in those jurisdictions. Significant disputes may arise with these tax authorities involving issues of the timing and amount of income and deductions, the use of tax credits and allocations of income among various tax jurisdictions because of differing interpretations of tax laws and regulations. We are no longer subject to U.S. federal income tax examinations for years ended on or before December 31, 2009, or to California state income tax examinations for years ended on or before December 31, 2008.
	During the three months ended March 31, 2015, the gross amount of our unrecognized tax benefits (UTBs) increased by approximately $100 million as a result of tax positions taken during the current year. The UTB balance decreased by approximately $70 million during the first quarter of 2015 due to a state tax audit settlement. Substantially all of the UTBs as of March 31, 2015, if recognized, would affect our effective tax rate.

Earnings_per_share

Earnings per share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings per share	Earnings per share
	The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include principally shares that may be issued under our stock option awards and restricted stock and performance unit awards, determined using the treasury stock method (collectively “dilutive securities”).
	The computation for basic and diluted EPS was as follows (in millions, except per share data):
		Three months ended
		March 31,
		2015		2014
	Income (Numerator):
	Net income for basic and diluted EPS	$	1,623	$	1,073
	Shares (Denominator):
	Weighted-average shares for basic EPS	761		757
	Effect of dilutive securities	9		11
	Weighted-average shares for diluted EPS	770		768
	Basic EPS	$	2.13	$	1.42
	Diluted EPS	$	2.11	$	1.4
	For the three months ended March 31, 2015 and 2014, the number of anti-dilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

Availableforsale_investments

Available-for-sale investments	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Available-for-sale investments	Available-for-sale investments
	The amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security were as follows (in millions):
	Type of security as of March 31, 2015	Amortized		Gross			Gross			Estimated
		cost		unrealized			unrealized			fair
				gains			losses			value
	U.S. Treasury securities	$	3,246	$	39		$	(1	)	$	3,284
	Other government-related debt securities:
	U.S.	516		2			—			518
	Foreign and other	1,690		41			(6		)	1,725
	Corporate debt securities:
	Financial	6,525		56			(5		)	6,576
	Industrial	6,872		60			(30		)	6,902
	Other	672		7			(1		)	678
	Residential mortgage-backed securities	1,600		10			(6		)	1,604
	Other mortgage- and asset-backed securities	1,708		3			(37		)	1,674
	Money market mutual funds	2,035		—			—			2,035
	Other short-term interest-bearing securities	1,520		—			—			1,520
	Total interest-bearing securities	26,384		218			(86		)	26,516
	Equity securities	98		62			(2		)	158
	Total available-for-sale investments	$	26,482	$	280		$	(88	)	$	26,674
	Type of security as of December 31, 2014	Amortized		Gross			Gross			Estimated
		cost		unrealized			unrealized			fair
				gains			losses			value
	U.S. Treasury securities	$	3,632	$	22		$	(8	)	$	3,646
	Other government-related debt securities:
	U.S.	530		1			(3		)	528
	Foreign and other	1,572		21			(24		)	1,569
	Corporate debt securities:
	Financial	6,036		21			(16		)	6,041
	Industrial	6,394		23			(66		)	6,351
	Other	650		3			(4		)	649
	Residential mortgage-backed securities	1,708		4			(10		)	1,702
	Other mortgage- and asset-backed securities	1,837		—			(41		)	1,796
	Money market mutual funds	3,004		—			—			3,004
	Other short-term interest-bearing securities	1,302		—			—			1,302
	Total interest-bearing securities	26,665		95			(172		)	26,588
	Equity securities	98		48			(2		)	144
	Total available-for-sale investments	$	26,763	$	143		$	(174	)	$	26,732
	The fair values of available-for-sale investments by classification in the Condensed Consolidated Balance Sheets were as follows (in millions):
	Classification in the Condensed Consolidated Balance Sheets	March 31,		December 31,
		2015		2014
	Cash and cash equivalents	$	2,262	$	3,293
	Marketable securities	24,254		23,295
	Other assets — noncurrent	158		144
	Total available-for-sale investments	$	26,674	$	26,732
	Cash and cash equivalents in the table above excludes cash of $602 million and $438 million as of March 31, 2015, and December 31, 2014, respectively.
	The fair values of available-for-sale interest-bearing security investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions):
	Contractual maturity	March 31,		December 31,
		2015		2014
	Maturing in one year or less	$	4,015	$	4,936
	Maturing after one year through three years	7,428		6,829
	Maturing after three years through five years	8,146		7,840
	Maturing after five years through ten years	3,471		3,267
	Maturing after ten years	178		218
	Mortgage- and asset-backed securities	3,278		3,498
	Total interest-bearing securities	$	26,516	$	26,588
	For the three months ended March 31, 2015 and 2014, realized gains totaled $36 million and $28 million, respectively, and realized losses totaled $71 million and $26 million, respectively. The cost of securities sold is based on the specific identification method.
	The unrealized losses on available-for-sale investments and their related fair values were as follows (in millions):
		Less than 12 months					12 months or greater
	Type of security as of March 31, 2015	Fair value		Unrealized losses			Fair value			Unrealized losses
	U.S. Treasury securities	$	635	$	(1	)	$	30		$	—
	Other government-related debt securities:
	U.S.	86		—			35			—
	Foreign and other	281		(4		)	71			(2		)
Corporate debt securities:
Financial	859		(4		)	65			(1		)
Industrial	2,188		(27		)	170			(2		)
Other	159		(2		)	—			—
Residential mortgage-backed securities	320		(2		)	277			(4		)
Other mortgage- and asset-backed securities	462		(7		)	456			(30		)
Equity securities	5		(2		)	—			—
Total	$	4,995	$	(49	)	$	1,104		$	(39	)
	Less than 12 months					12 months or greater
Type of security as of December 31, 2014	Fair value		Unrealized losses			Fair value			Unrealized losses
U.S. Treasury securities	$	1,770	$	(7	)	$	171		$	(1	)
Other government-related debt securities:
U.S.	160		—			178			(3		)
Foreign and other	514		(14		)	159			(10		)
Corporate debt securities:
Financial	3,150		(14		)	158			(2		)
Industrial	3,931		(62		)	222			(4		)
Other	354		(4		)	5			—
Residential mortgage-backed securities	614		(4		)	413			(6		)
Other mortgage- and asset-backed securities	1,071		(8		)	561			(33		)
Equity securities	5		(2		)	—			—
Total	$	11,569	$	(115	)	$	1,867		$	(59	)
The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.
We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security, and the intent to sell, or whether we will more likely than not be required to sell, the security before recovery of its amortized cost basis. Our assessment of whether a security is other-than-temporarily impaired could change in the future due to new developments or changes in assumptions related to any particular security. As of March 31, 2015, and December 31, 2014, we believe the cost bases for our available-for-sale investments were recoverable in all material respects.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories
	Inventories consisted of the following (in millions):
		March 31,		December 31,
		2015		2014
	Raw materials	$	212	$	198
	Work in process	1,282		1,551
	Finished goods	1,192		898
	Total inventories	$	2,686	$	2,647

Goodwill_and_other_intangible_

Goodwill and other intangible assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets
	Goodwill
	The changes in the carrying amounts of goodwill were as follows (in millions):
		Three months ended March 31,
		2015			2014
	Beginning balance	$	14,788		$	14,968
	Goodwill related to acquisitions of businesses(1)	—			(130		)
	Currency translation and other adjustments	(67		)	(6		)
	Ending balance	$	14,721		$	14,832
	(1)	Composed of goodwill recognized on the acquisition dates of business combinations and subsequent adjustments to these amounts resulting from changes to the acquisition date fair values of net assets acquired in the business combinations recorded during their respective measurement periods.
	Identifiable intangible assets
	Identifiable intangible assets consisted of the following (in millions):
		March 31, 2015								December 31, 2014
		Gross			Accumulated			Intangible		Gross		Accumulated			Intangible
		carrying			amortization			assets, net		carrying		amortization			assets, net
		amount								amount
	Finite-lived intangible assets:
	Developed product technology rights	$	10,786		$	(4,361	)	$	6,425	$	10,826	$	(4,155	)	$	6,671
	Licensing rights	3,232			(770		)	2,462		3,236		(696		)	2,540
	R&D technology rights	1,136			(577		)	559		1,167		(569		)	598
	Marketing-related rights	1,223			(544		)	679		1,241		(512		)	729
	Total finite-lived intangible assets	16,377			(6,252		)	10,125		16,470		(5,932		)	10,538
	Indefinite-lived intangible assets:
	In-process research and development (IPR&D)	2,140			—			2,140		2,155		—			2,155
	Total identifiable intangible assets	$	18,517		$	(6,252	)	$	12,265	$	18,625	$	(5,932	)	$	12,693
	Developed product technology rights consist of rights related to marketed products acquired in business combinations. Licensing rights are composed primarily of contractual rights acquired in business combinations to receive future milestones, royalties and profit sharing payments, capitalized payments to third parties for milestones related to regulatory approvals to commercialize products and up-front payments associated with royalty obligations for marketed products. R&D technology rights consist of technology used in R&D with alternative future uses. Marketing-related intangible assets are composed primarily of rights related to the sale and distribution of marketed products.
	IPR&D consists of R&D projects acquired in a business combination which are not complete due to remaining technological risks and/or lack of receipt of the required regulatory approvals. These projects include Kyprolis® (carfilzomib) for Injection and oprozomib acquired in the acquisition of Onyx Pharmaceuticals, Inc. (Onyx), AMG 416 acquired in the acquisition of KAI Pharmaceuticals and talimogene laherparepvec acquired in the acquisition of BioVex Group, Inc. (BioVex).
	In February 2015, we announced that the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) will jointly review our talimogene laherparepvec Biologics License Application (BLA) at a meeting on April 29, 2015. The FDA will consider the advisory committees' recommendations in its review of our talimogene laherparepvec BLA for the treatment of patients with injectable regionally or distantly metastatic melanoma. As of March 31, 2015, the carrying value of the IPR&D for talimogene laherparepvec was $675 million.
	For all IPR&D projects, there are major risks and uncertainties associated with the timely and successful completion of development and commercialization of these product candidates, including our ability to confirm their safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not able to market a human therapeutic without obtaining regulatory approvals, and such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans, impact the revenues a product can generate. Consequently, the eventual realized value, if any, of these acquired IPR&D projects may vary from their estimated fair values. IPR&D projects are reviewed annually for impairment and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For example, if the BLA for talimogene laherparepvec is not approved for treatment of patients with injectable regionally or distantly metastatic melanoma, we would be required to test the talimogene laherparepvec IPR&D asset for impairment again.
	During the three months ended March 31, 2015 and 2014, we recognized amortization charges associated with our finite-lived intangible assets of $341 million and $357 million, respectively. The total estimated amortization charges for our finite-lived intangible assets for the nine months ending December 31, 2015, and the years ending December 31, 2016, 2017, 2018, 2019 and 2020, are $1.0 billion, $1.3 billion, $1.2 billion, $1.0 billion, $939 million and $891 million, respectively.

Financing_arrangements

Financing arrangements	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Financing arrangements	Financing arrangements
	The carrying values and the fixed contractual coupon rates, as applicable, of our long-term borrowings were as follows (in millions):
		March 31,			December 31,
		2015			2014
	2.30% notes due 2016 (2.30% 2016 Notes)	$	750		$	749
	2.50% notes due 2016 (2.50% 2016 Notes)	1,000			1,000
	Floating Rate Notes due 2017	600			600
	1.25% notes due 2017 (1.25% 2017 Notes)	849			849
	2.125% notes due 2017 (2.125% 2017 Notes)	1,249			1,249
	5.85% notes due 2017 (5.85% 2017 Notes)	1,100			1,100
	6.15% notes due 2018 (6.15% 2018 Notes)	500			500
	Term Loan due 2018	4,250			4,375
	4.375% euro-denominated notes due 2018 (4.375% 2018 euro Notes)	599			668
	Floating Rate Notes due 2019	250			250
	2.20% notes due 2019 (2.20% 2019 Notes)	1,398			1,398
	5.70% notes due 2019 (5.70% 2019 Notes)	999			999
	2.125% euro-denominated notes due 2019 (2.125% 2019 euro Notes)	722			814
	4.50% notes due 2020 (4.50% 2020 Notes)	300			300
	3.45% notes due 2020 (3.45% 2020 Notes)	898			898
	4.10% notes due 2021 (4.10% 2021 Notes)	998			998
	3.875% notes due 2021 (3.875% 2021 Notes)	1,747			1,747
	3.625% notes due 2022 (3.625% 2022 Notes)	747			747
	3.625% notes due 2024 (3.625% 2024 Notes)	1,398			1,398
	5.50% pound-sterling-denominated notes due 2026 (5.50% 2026 pound sterling Notes)	699			735
	4.00% pound-sterling-denominated notes due 2029 (4.00% 2029 pound sterling Notes)	1,023			1,076
	6.375% notes due 2037 (6.375% 2037 Notes)	899			899
	6.90% notes due 2038 (6.90% 2038 Notes)	499			499
	6.40% notes due 2039 (6.40% 2039 Notes)	996			996
	5.75% notes due 2040 (5.75% 2040 Notes)	697			697
	4.95% notes due 2041 (4.95% 2041 Notes)	596			596
	5.15% notes due 2041 (5.15% 2041 Notes)	2,233			2,233
	5.65% notes due 2042 (5.65% 2042 Notes)	1,245			1,245
	5.375% notes due 2043 (5.375% 2043 Notes)	1,000			1,000
	Other notes	100			100
	Total debt	30,341			30,715
	Less current portion	(500		)	(500		)
	Total noncurrent debt	$	29,841		$	30,215
	Debt repayments
	During the three months ended March 31, 2015, we repaid $125 million of principal on our Term Loan Credit Facility.

Stockholders_equity

Stockholders' equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' equity	Stockholders’ equity
	Stock repurchase program
	Activity under our stock repurchase program was as follows (in millions):
		2015							2014
		Shares			Dollars				Shares			Dollars
	First quarter	2.9			$	451			—			$	—
	As of March 31, 2015, $3.4 billion remained available under our stock repurchase program.
	Dividends
	On December 17, 2014, the Board of Directors declared a quarterly cash dividend of $0.79 per share of common stock, which was paid on March 6, 2015. On March 4, 2015, the Board of Directors declared a quarterly cash dividend of $0.79 per share of common stock, which will be paid on June 5, 2015, to all stockholders of record as of the close of business on May 14, 2015.
	Accumulated other comprehensive income
	The components of accumulated other comprehensive income (AOCI) were as follows (in millions):
		Foreign				Cash flow				Available-for-sale				Other			AOCI
		currency				hedges				securities
		translation
	Balance as of December 31, 2014	$	(264	)		$	290			$	(19	)		$	(15	)	$	(8	)
	Foreign currency translation adjustments	(184		)		—				—				—			(184		)
	Unrealized gains	—				168				188				—			356
	Reclassification adjustments to income	—				114				35				—			149
	Income taxes	11				(104		)		(83		)		—			(176		)
	Balance as of March 31, 2015	$	(437	)		$	468			$	121			$	(15	)	$	137
	The reclassifications out of AOCI to earnings were as follows (in millions):
			Amounts reclassified out of AOCI
	Components of AOCI		Three months ended March 31, 2015				Three months ended March 31, 2014				Line item affected in the Statements of Income
	Cash flow hedges:
	Foreign currency contract gains		$	69			$	—			Product sales
	Cross-currency swap contract (losses) gains		(183		)		14				Interest and other income, net
			(114		)		14				Total before income tax
			41				(5		)		Tax benefit/(expense)
			$	(73	)		$	9			Net of taxes
	Available-for-sale securities:
	Net realized (losses) gains		$	(35	)		$	2			Interest and other income, net
			13				(1		)		Tax benefit/(expense)
			$	(22	)		$	1			Net of taxes

Fair_value_measurement

Fair value measurement	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement
	To estimate the fair value of our financial assets and liabilities we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:
	Level 1	—	Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access
	Level 2	—	Valuations for which all significant inputs are observable, either directly or indirectly, other than level 1 inputs
	Level 3	—	Valuations based on inputs that are unobservable and significant to the overall fair value measurement
	The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.
	The fair value of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis was as follows (in millions):
			Quoted prices in			Significant		Significant
			active markets for			other observable		unobservable
	Fair value measurement		identical assets			inputs		inputs
	as of March 31, 2015, using:		(Level 1)			(Level 2)		(Level 3)		Total
	Assets:
	Available-for-sale investments:
	U.S. Treasury securities		$	3,284		$	—	$	—	$	3,284
	Other government-related debt securities:
	U.S.		—			518		—		518
	Foreign and other		—			1,725		—		1,725
	Corporate debt securities:
	Financial		—			6,576		—		6,576
	Industrial		—			6,902		—		6,902
	Other		—			678		—		678
	Residential mortgage-backed securities		—			1,604		—		1,604
	Other mortgage- and asset-backed securities		—			1,674		—		1,674
	Money market mutual funds		2,035			—		—		2,035
	Other short-term interest-bearing securities		—			1,520		—		1,520
	Equity securities		158			—		—		158
	Derivatives:
	Foreign currency contracts		—			679		—		679
	Interest rate swap contracts		—			109		—		109
	Total assets		$	5,477		$	21,985	$	—	$	27,462
	Liabilities:
	Derivatives:
	Foreign currency contracts		$	—		$	12	$	—	$	12
	Cross-currency swap contracts		—			197		—		197
	Contingent consideration obligations in connection with business combinations		—			—		215		215
	Total liabilities		$	—		$	209	$	215	$	424
			Quoted prices in			Significant		Significant
			active markets for			other observable		unobservable
	Fair value measurement		identical assets			inputs		inputs
	as of December 31, 2014, using:		(Level 1)			(Level 2)		(Level 3)		Total
	Assets:
	Available-for-sale investments:
	U.S. Treasury securities		$	3,646		$	—	$	—	$	3,646
	Other government-related debt securities:
	U.S.		—			528		—		528
	Foreign and other		—			1,569		—		1,569
	Corporate debt securities:
	Financial		—			6,041		—		6,041
	Industrial		—			6,351		—		6,351
	Other		—			649		—		649
	Residential mortgage-backed securities		—			1,702		—		1,702
	Other mortgage- and asset-backed securities		—			1,796		—		1,796
	Money market mutual funds		3,004			—		—		3,004
	Other short-term interest-bearing securities		—			1,302		—		1,302
	Equity securities		144			—		—		144
	Derivatives:
	Foreign currency contracts		—			360		—		360
	Cross-currency swap contracts		—			32		—		32
	Interest rate swap contracts		—			46		—		46
	Total assets		$	6,794		$	20,376	$	—	$	27,170
	Liabilities:
	Derivatives:
	Foreign currency contracts		$	—		$	4	$	—	$	4
	Cross-currency swap contracts		—			12		—		12
Interest rate swap contracts		—			26		—		26
Contingent consideration obligations in connection with business combinations		—			—		215		215
Total liabilities		$	—		$	42	$	215	$	257
The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets with no valuation adjustment.
Most of our other government-related and corporate debt securities are investment grade with maturity dates of five years or less from the balance sheet date. Our other government-related debt securities portfolio is composed of securities with weighted-average credit ratings of A- or equivalent by Standard & Poor's Financial Services LLC (S&P) or Fitch, Inc. (Fitch), A by Moody's Investor Service, Inc. (Moody's); and our corporate debt securities portfolio has a weighted-average credit rating of BBB+ or equivalent by S&P or Moody's, and A- by Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.
Our residential mortgage-, other mortgage- and asset-backed securities portfolio is composed entirely of senior tranches, with credit ratings of AAA or equivalent by S&P, Moody's or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.
We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near term maturity dates.
All of our foreign currency forward and option derivatives contracts have maturities of three years or less and all are with counterparties that have minimum credit ratings of A- or equivalent by S&P, Moody’s or Fitch. We estimated the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency rates, London Interbank Offered Rates (LIBOR) cash and swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts also include implied volatility measures. These inputs, where applicable, are at commonly quoted intervals. See Note 11, Derivative instruments.
Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A- or equivalent by S&P, Moody’s or Fitch. We estimated the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 11, Derivative instruments.
Our interest rate swap contracts are with counterparties that have minimum credit ratings of A- or equivalent by S&P, Moody’s or Fitch. We estimated the fair values of these contracts by using an income-based industry standard valuation model for which all significant inputs were observable either directly or indirectly. These inputs included LIBOR, swap rates and obligor credit default swap rates.
Contingent consideration obligations
We have incurred contingent consideration obligations as a result of our acquisition of a business and upon the assumption of contingent consideration obligations incurred by an acquired company discussed below. These contingent consideration obligations are recorded at their estimated fair values, and we revalue these obligations each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to product candidates acquired in the business combinations and are reviewed quarterly by management in our R&D and commercial sales organizations. These inputs include, as applicable, estimated probabilities and timing of achieving specified regulatory and commercial milestones and estimated annual sales. Significant changes which increase or decrease the probabilities of achieving the related regulatory and commercial events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of these obligations, as applicable. Changes in fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.
The changes in carrying amounts of contingent consideration obligations were as follows (in millions):
	Three months ended March 31,
	2015			2014
Beginning balance	$	215		$	595
Net changes in valuation	—			1
Ending balance	$	215		$	596
As a result of our acquisition of BioVex in March 2011, we are obligated to pay its former shareholders up to $575 million of additional consideration contingent upon achieving separate regulatory and sales-related milestones with regard to talimogene laherparepvec, which was acquired in the acquisition. As a result of filing the BLA in the United States, we made a milestone payment of $125 million to the former BioVex shareholders during 2014. The remaining potential milestone payments include: (i) $125 million upon the first commercial sale in the United States following receipt of marketing approval for use of the product in specified patient populations, (ii) $125 million upon achievement of an agreed level of worldwide sales within a specified period of time and (iii) up to $200 million of additional consideration of varying amounts upon achievement of certain other regulatory and sales-related milestones.
We estimate the fair values of the obligations to the former shareholders of BioVex by using probability-adjusted discounted cash flows. As a result of our quarterly review of the key assumptions, there was no change in the estimated aggregate fair value of the contingent consideration during the three months ended March 31, 2015 and 2014, respectively.
We assumed contingent consideration obligations upon the acquisition of Onyx arising from Onyx's 2009 acquisition of Proteolix, Inc. These contingent consideration obligations were comprised of two separate milestone payments of $150 million each payable if Kyprolis® received specified marketing approvals for relapsed multiple myeloma on or before March 31, 2016, by each of the FDA and the European Medicines Agency (EMA). In December 2014, we renegotiated the terms of these milestones and settled the contingent consideration obligations with the former shareholders of Proteolix, Inc. by agreeing to make a single payment of $225 million. This amount was paid during the first quarter of 2015.
There have been no transfers of assets or liabilities between the fair value measurement levels, and there were no material remeasurements to fair value during the three months ended March 31, 2015 and 2014, of assets and liabilities that are not measured at fair value on a recurring basis.
Summary of the fair value of other financial instruments
Cash equivalents
The estimated fair values of cash equivalents approximate their carrying values due to the short-term nature of these financial instruments.
Borrowings
We estimated the fair value of our long-term debt (Level 2) by taking into consideration indicative prices obtained from a third-party financial institution that utilizes industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; credit spreads; benchmark yields; foreign currency exchange rates, as applicable; and other observable inputs. As of March 31, 2015, and December 31, 2014, the aggregate fair values of our long-term debt were $33.5 billion and $33.6 billion, respectively, and the carrying values were $30.3 billion and $30.7 billion, respectively.

Derivative_instruments

Derivative instruments	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments	Derivative instruments
	The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to these exposures, we utilize or have utilized certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.
	Cash flow hedges
	We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by the corresponding increases and decreases in our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations on our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods. As of March 31, 2015, and December 31, 2014, we had open foreign currency forward contracts with notional amounts of $3.7 billion and $3.8 billion, respectively, and open foreign currency option contracts with notional amounts of $352 million and $271 million, respectively. These foreign currency forward and option contracts, primarily euro based, have been designated as cash flow hedges, and accordingly, the effective portions of the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to earnings in the same periods during which the hedged transactions affect earnings.
	To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. Under the terms of these contracts, we paid euros/pounds sterling and received U.S. dollars for the notional amounts at the inception of the contracts, and we exchange interest payments based on these notional amounts at fixed rates over the lives of the contracts in which we pay U.S. dollars and receive euros/pounds sterling. In addition, we will pay U.S. dollars to and receive euros/pounds sterling from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged notes, effectively converting the interest payments and principal repayment on these notes from euros/pounds sterling to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges, and accordingly, the effective portions of the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to earnings in the same periods during which the hedged debt affects earnings.
	The notional amounts and interest rates of our cross-currency swaps are as follows (notional amounts in millions):
		Foreign currency							U.S. dollars
	Hedged notes	Notional amount				Interest rate			Notional amount			Interest rate
	2.125% 2019 euro Notes	€	675			2.125	%		$	864		2.6	%
	5.50% 2026 pound sterling Notes	£	475			5.5	%		$	747		6	%
	4.00% 2029 pound sterling Notes	£	700			4	%		$	1,111		4.5	%
	The effective portions of the unrealized gain/(loss) recognized in other comprehensive income for our derivative instruments designated as cash flow hedges were as follows (in millions):
		Three months ended
		March 31,
	Derivatives in cash flow hedging relationships	2015				2014
	Foreign currency contracts	$	392			$	13
	Cross-currency swap contracts	(224		)		4
	Total	$	168			$	17
	The locations in the Condensed Consolidated Statements of Income and the effective portions of the gain/(loss) reclassified out of AOCI into earnings for our derivative instruments designated as cash flow hedges were as follows (in millions):
				Three months ended
				March 31,
	Derivatives in cash flow hedging relationships	Statements of Income location		2015				2014
	Foreign currency contracts	Product sales		$	69			$	—
	Cross-currency swap contracts	Interest and other income, net		(183		)		14
	Total			$	(114	)		$	14
	No portions of our cash flow hedge contracts are excluded from the assessment of hedge effectiveness, and the gains and losses of the ineffective portions of these hedging instruments were not material for the three months ended March 31, 2015 and 2014. As of March 31, 2015, the amounts expected to be reclassified out of AOCI into earnings over the next 12 months are approximately $358 million of net gains on our foreign currency and cross-currency swap contracts and approximately $1 million of losses on forward interest rate contracts.
	Fair value hedges
	To achieve a desired mix of fixed and floating interest rates on our long-term debt, we entered into interest rate swap contracts, which qualified and are designated as fair value hedges. The terms of these interest rate swap contracts correspond to the related hedged debt instruments and effectively converted a fixed interest rate coupon to a floating LIBOR-based coupon over the lives of the respective notes. We had interest rate swap agreements as of March 31, 2015 and December 31, 2014, with aggregate notional amounts of $6.65 billion. The contracts have rates that range from three-month LIBOR plus 0.4% to three-month LIBOR plus 2.0%.
	For derivative instruments that are designated and qualify as fair value hedges, the unrealized gain or loss on the derivative resulting from the change in fair value during the period as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk is recognized in current earnings. For the three months ended March 31, 2015 and 2014, we included the unrealized losses on the hedged debt of $89 million and $62 million, respectively, in the same line item, Interest expense, net, in the Condensed Consolidated Statements of Income, as the offsetting unrealized gains of $89 million and $62 million, respectively, on the related interest rate swap agreements.
	Derivatives not designated as hedges
	We enter into foreign currency forward contracts that are not designated as hedging transactions to reduce our exposure to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies. These exposures are hedged on a month-to-month basis. As of March 31, 2015, and December 31, 2014, the total notional amounts of these foreign currency forward contracts were $957 million and $875 million, respectively.
	The location in the Condensed Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for our derivative instruments not designated as hedging instruments were as follows (in millions):
				Three months ended
				March 31,
	Derivatives not designated as hedging instruments	Statements of Income location		2015				2014
	Foreign currency contracts	Interest and other income, net		$	(29	)		$	2
	The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):
		Derivative assets						Derivative liabilities
	31-Mar-15	Balance Sheet location		Fair value				Balance Sheet location		Fair value
	Derivatives designated as hedging instruments:
	Cross-currency swap contracts	Other current assets/ Other noncurrent assets		$	—			Accrued liabilities/ Other noncurrent liabilities		$	197
	Foreign currency contracts	Other current assets/ Other noncurrent assets		667				Accrued liabilities/ Other noncurrent liabilities		—
	Interest rate swap contracts	Other current assets/ Other noncurrent assets		109				Accrued liabilities/ Other noncurrent liabilities		—
	Total derivatives designated as hedging instruments			776						197
	Derivatives not designated as hedging instruments:
	Foreign currency contracts	Other current assets		12				Accrued liabilities		12
	Total derivatives not designated as hedging instruments			12						12
	Total derivatives			$	788					$	209
		Derivative assets						Derivative liabilities
	31-Dec-14	Balance Sheet location		Fair value				Balance Sheet location		Fair value
	Derivatives designated as hedging instruments:
	Cross-currency swap contracts	Other current assets/ Other noncurrent assets		$	32			Accrued liabilities/ Other noncurrent liabilities		$	12
	Foreign currency contracts	Other current assets/ Other noncurrent assets		356				Accrued liabilities/ Other noncurrent liabilities		—
	Interest rate swap contracts	Other current assets/ Other noncurrent assets		46				Accrued liabilities/ Other noncurrent liabilities		26
	Total derivatives designated as hedging instruments			434						38
	Derivatives not designated as hedging instruments:
	Foreign currency contracts	Other current assets		4				Accrued liabilities		4
	Total derivatives not designated as hedging instruments			4						4
	Total derivatives			$	438					$	42
	Our derivative contracts that were in liability positions as of March 31, 2015, contain certain credit-risk-related contingent provisions that would be triggered if: (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due to or from a counterparty under these contracts may only be offset against other amounts due to or from the same counterparty if an event of default or termination, as defined, were to occur.
	The cash flow effects of our derivative contracts for the three months ended March 31, 2015 and 2014, are included within Net cash provided by operating activities in the Condensed Consolidated Statements of Cash Flows.

Contingencies_and_commitments

Contingencies and commitments	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies and commitments	Contingencies and commitments
	Contingencies
	In the ordinary course of business, we are involved in various legal proceedings and other matters—including those discussed in this Note—that are complex in nature and have outcomes that are difficult to predict. See Note 18, Contingencies and commitments to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2014, for further discussion of certain of our legal proceedings and other matters.
	We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.
	Our legal proceedings range from cases brought by a single plaintiff to class actions with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims—including but not limited to patent infringement, marketing, pricing and trade practices and securities law—some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing or in Note 18, Contingencies and commitments, to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2014, plaintiffs seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process (which in complex proceedings of the sort faced by us often extend for several years). As a result, none of the matters described in this filing have progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.
	Certain recent developments concerning our legal proceedings and other matters are discussed below:
	Onyx Litigation
	The trial date in this class action lawsuit filed in connection with Amgen’s acquisition of Onyx has been set for April 28, 2016.
	Federal Securities Litigation - In re Amgen Inc. Securities Litigation
	The trial date in this federal securities class action has been set for July 12, 2016.
	Sanofi/Regeneron Patent Litigation
	The trial date in this patent infringement case has been set for March 7, 2016.
	Sandoz Filgrastim Litigation
	On March 19, 2015, the U.S. District Court for the Northern District of California (the California Northern District Court) issued an order dismissing with prejudice Amgen’s claims for unfair competition under California Business & Professions Code § 17200 and conversion under California common law, and entered judgment in favor of Sandoz Inc. (Sandoz) on Sandoz’s cross-motion for partial judgment on the pleadings. The order also denied Amgen’s motion for a preliminary injunction, as well as Amgen’s motion for partial judgment on the pleadings. On a joint motion of the parties, on March 25, 2015 the California Northern District Court entered final judgment on the claims and counterclaims decided by the court’s March 19th order. The remaining patent infringement claim, counterclaim and defenses were stayed by the court pending appeal. On March 25, 2015, Amgen appealed the judgment in favor of Sandoz and the denial of Amgen’s motion for preliminary injunction to the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). The Federal Circuit Court granted Amgen’s motion for an expedited appeal with the hearing date on the appeal scheduled for June 3, 2015. On April 17, 2015, Amgen filed a motion for an injunction pending appeal with the Federal Circuit Court.

Summary_of_significant_account1

Summary of significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Business	Business
	Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation	Basis of presentation
	The financial information for the three months ended March 31, 2015 and 2014, is unaudited but includes all adjustments (consisting of only normal recurring adjustments, unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
	The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2014.
Principles of consolidation	Principles of consolidation
	The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	Use of estimates
	The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net	Property, plant and equipment, net
	Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $7.2 billion and $7.0 billion as of March 31, 2015, and December 31, 2014, respectively.
Recent accounting pronouncements	Recent accounting pronouncements
	In May 2014, a new accounting standard was issued that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. This new standard will be effective for interim and annual periods beginning January 1, 2017, and is required to be adopted using either a full retrospective or a modified retrospective approach, and early adoption is not permitted. We are currently evaluating the impact that this new standard will have on our financial statements.
	In April 2015, a new accounting standard was issued that amends the presentation for debt issuance costs. Upon adoption, such costs shall be presented on our consolidated balance sheets as a direct deduction from the carrying amount of the related debt liability and not as a deferred charge presented in Other assets on our consolidated balance sheets. This new standard will be effective for interim and annual periods beginning on January 1, 2016, and is required to be retrospectively adopted. Adoption of this new standard is not expected to have a material impact on our consolidated balance sheets or related disclosures.

Restructuring_Tables

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Summary of restructuring plan charges by type of activity	The following table summarizes the charges recorded related to the restructuring plan by type of activity and the locations recognized within the Condensed Consolidated Statement of Income (in millions):
			During the three months ended March 31, 2015
			Separation costs			Asset impairments			Accelerated depreciation		Other		Total
	Cost of sales		$	—		$	—		$	13	$	1	$	14
	Research and development		—			—			14		3		17
	Selling, general and administrative		—			—			1		3		4
	Other		48			—			—		9		57
	Total		$	48		$	—		$	28	$	16	$	92
Restructuring liabilities roll forward	The following table summarizes the charges and spending related to the restructuring plan (in millions):
		During the three months ended March 31, 2015
		Separation costs			Other			Total
	Restructuring liabilities as of December 31, 2014	$	221		$	23		$	244
	Expense	48			9			57
	Payments	(99		)	(10		)	(109		)
	Restructuring liabilities as of March 31, 2015	$	170		$	22		$	192

Earnings_per_share_Tables

Earnings per share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Computation for basic and diluted earnings per share	The computation for basic and diluted EPS was as follows (in millions, except per share data):
		Three months ended
		March 31,
		2015		2014
	Income (Numerator):
	Net income for basic and diluted EPS	$	1,623	$	1,073
	Shares (Denominator):
	Weighted-average shares for basic EPS	761		757
	Effect of dilutive securities	9		11
	Weighted-average shares for diluted EPS	770		768
	Basic EPS	$	2.13	$	1.42
	Diluted EPS	$	2.11	$	1.4

Availableforsale_investments_T

Available-for-sale investments (Tables)	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security	The amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security were as follows (in millions):
	Type of security as of March 31, 2015	Amortized		Gross			Gross			Estimated
		cost		unrealized			unrealized			fair
				gains			losses			value
	U.S. Treasury securities	$	3,246	$	39		$	(1	)	$	3,284
	Other government-related debt securities:
	U.S.	516		2			—			518
	Foreign and other	1,690		41			(6		)	1,725
	Corporate debt securities:
	Financial	6,525		56			(5		)	6,576
	Industrial	6,872		60			(30		)	6,902
	Other	672		7			(1		)	678
	Residential mortgage-backed securities	1,600		10			(6		)	1,604
	Other mortgage- and asset-backed securities	1,708		3			(37		)	1,674
	Money market mutual funds	2,035		—			—			2,035
	Other short-term interest-bearing securities	1,520		—			—			1,520
	Total interest-bearing securities	26,384		218			(86		)	26,516
	Equity securities	98		62			(2		)	158
	Total available-for-sale investments	$	26,482	$	280		$	(88	)	$	26,674
	Type of security as of December 31, 2014	Amortized		Gross			Gross			Estimated
		cost		unrealized			unrealized			fair
				gains			losses			value
	U.S. Treasury securities	$	3,632	$	22		$	(8	)	$	3,646
	Other government-related debt securities:
	U.S.	530		1			(3		)	528
	Foreign and other	1,572		21			(24		)	1,569
	Corporate debt securities:
	Financial	6,036		21			(16		)	6,041
	Industrial	6,394		23			(66		)	6,351
	Other	650		3			(4		)	649
	Residential mortgage-backed securities	1,708		4			(10		)	1,702
	Other mortgage- and asset-backed securities	1,837		—			(41		)	1,796
	Money market mutual funds	3,004		—			—			3,004
	Other short-term interest-bearing securities	1,302		—			—			1,302
	Total interest-bearing securities	26,665		95			(172		)	26,588
	Equity securities	98		48			(2		)	144
	Total available-for-sale investments	$	26,763	$	143		$	(174	)	$	26,732
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets	The fair values of available-for-sale investments by classification in the Condensed Consolidated Balance Sheets were as follows (in millions):
	Classification in the Condensed Consolidated Balance Sheets	March 31,		December 31,
		2015		2014
	Cash and cash equivalents	$	2,262	$	3,293
	Marketable securities	24,254		23,295
	Other assets — noncurrent	158		144
	Total available-for-sale investments	$	26,674	$	26,732
Fair values of available-for-sale interest-bearing security investments by contractual maturity	The fair values of available-for-sale interest-bearing security investments by contractual maturity, except for mortgage- and asset-backed securities that do not have a single maturity date, were as follows (in millions):
	Contractual maturity	March 31,		December 31,
		2015		2014
	Maturing in one year or less	$	4,015	$	4,936
	Maturing after one year through three years	7,428		6,829
	Maturing after three years through five years	8,146		7,840
	Maturing after five years through ten years	3,471		3,267
	Maturing after ten years	178		218
	Mortgage- and asset-backed securities	3,278		3,498
	Total interest-bearing securities	$	26,516	$	26,588
Available-for-sale securities, fair value and unrealized losses	The unrealized losses on available-for-sale investments and their related fair values were as follows (in millions):
		Less than 12 months					12 months or greater
	Type of security as of March 31, 2015	Fair value		Unrealized losses			Fair value			Unrealized losses
	U.S. Treasury securities	$	635	$	(1	)	$	30		$	—
	Other government-related debt securities:
	U.S.	86		—			35			—
	Foreign and other	281		(4		)	71			(2		)
	Corporate debt securities:
	Financial	859		(4		)	65			(1		)
	Industrial	2,188		(27		)	170			(2		)
	Other	159		(2		)	—			—
	Residential mortgage-backed securities	320		(2		)	277			(4		)
	Other mortgage- and asset-backed securities	462		(7		)	456			(30		)
	Equity securities	5		(2		)	—			—
	Total	$	4,995	$	(49	)	$	1,104		$	(39	)
		Less than 12 months					12 months or greater
	Type of security as of December 31, 2014	Fair value		Unrealized losses			Fair value			Unrealized losses
	U.S. Treasury securities	$	1,770	$	(7	)	$	171		$	(1	)
	Other government-related debt securities:
	U.S.	160		—			178			(3		)
	Foreign and other	514		(14		)	159			(10		)
	Corporate debt securities:
	Financial	3,150		(14		)	158			(2		)
	Industrial	3,931		(62		)	222			(4		)
	Other	354		(4		)	5			—
	Residential mortgage-backed securities	614		(4		)	413			(6		)
	Other mortgage- and asset-backed securities	1,071		(8		)	561			(33		)
	Equity securities	5		(2		)	—			—
	Total	$	11,569	$	(115	)	$	1,867		$	(59	)

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories consisted of the following (in millions):
		March 31,		December 31,
		2015		2014
	Raw materials	$	212	$	198
	Work in process	1,282		1,551
	Finished goods	1,192		898
	Total inventories	$	2,686	$	2,647

Goodwill_and_other_intangible_1

Goodwill and other intangible assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	The changes in the carrying amounts of goodwill were as follows (in millions):
		Three months ended March 31,
		2015			2014
	Beginning balance	$	14,788		$	14,968
	Goodwill related to acquisitions of businesses(1)	—			(130		)
	Currency translation and other adjustments	(67		)	(6		)
	Ending balance	$	14,721		$	14,832
	(1)	Composed of goodwill recognized on the acquisition dates of business combinations and subsequent adjustments to these amounts resulting from changes to the acquisition date fair values of net assets acquired in the business combinations recorded during their respective measurement periods.
Schedule of identifiable intangible assets	Identifiable intangible assets consisted of the following (in millions):
		March 31, 2015								December 31, 2014
		Gross			Accumulated			Intangible		Gross		Accumulated			Intangible
		carrying			amortization			assets, net		carrying		amortization			assets, net
		amount								amount
	Finite-lived intangible assets:
	Developed product technology rights	$	10,786		$	(4,361	)	$	6,425	$	10,826	$	(4,155	)	$	6,671
	Licensing rights	3,232			(770		)	2,462		3,236		(696		)	2,540
	R&D technology rights	1,136			(577		)	559		1,167		(569		)	598
	Marketing-related rights	1,223			(544		)	679		1,241		(512		)	729
	Total finite-lived intangible assets	16,377			(6,252		)	10,125		16,470		(5,932		)	10,538
	Indefinite-lived intangible assets:
	In-process research and development (IPR&D)	2,140			—			2,140		2,155		—			2,155
	Total identifiable intangible assets	$	18,517		$	(6,252	)	$	12,265	$	18,625	$	(5,932	)	$	12,693

Financing_arrangements_Tables

Financing arrangements (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Carrying values and the fixed contractual coupon rates of long-term borrowings	The carrying values and the fixed contractual coupon rates, as applicable, of our long-term borrowings were as follows (in millions):
		March 31,			December 31,
		2015			2014
	2.30% notes due 2016 (2.30% 2016 Notes)	$	750		$	749
	2.50% notes due 2016 (2.50% 2016 Notes)	1,000			1,000
	Floating Rate Notes due 2017	600			600
	1.25% notes due 2017 (1.25% 2017 Notes)	849			849
	2.125% notes due 2017 (2.125% 2017 Notes)	1,249			1,249
	5.85% notes due 2017 (5.85% 2017 Notes)	1,100			1,100
	6.15% notes due 2018 (6.15% 2018 Notes)	500			500
	Term Loan due 2018	4,250			4,375
	4.375% euro-denominated notes due 2018 (4.375% 2018 euro Notes)	599			668
	Floating Rate Notes due 2019	250			250
	2.20% notes due 2019 (2.20% 2019 Notes)	1,398			1,398
	5.70% notes due 2019 (5.70% 2019 Notes)	999			999
	2.125% euro-denominated notes due 2019 (2.125% 2019 euro Notes)	722			814
	4.50% notes due 2020 (4.50% 2020 Notes)	300			300
	3.45% notes due 2020 (3.45% 2020 Notes)	898			898
	4.10% notes due 2021 (4.10% 2021 Notes)	998			998
	3.875% notes due 2021 (3.875% 2021 Notes)	1,747			1,747
	3.625% notes due 2022 (3.625% 2022 Notes)	747			747
	3.625% notes due 2024 (3.625% 2024 Notes)	1,398			1,398
	5.50% pound-sterling-denominated notes due 2026 (5.50% 2026 pound sterling Notes)	699			735
	4.00% pound-sterling-denominated notes due 2029 (4.00% 2029 pound sterling Notes)	1,023			1,076
	6.375% notes due 2037 (6.375% 2037 Notes)	899			899
	6.90% notes due 2038 (6.90% 2038 Notes)	499			499
	6.40% notes due 2039 (6.40% 2039 Notes)	996			996
	5.75% notes due 2040 (5.75% 2040 Notes)	697			697
	4.95% notes due 2041 (4.95% 2041 Notes)	596			596
	5.15% notes due 2041 (5.15% 2041 Notes)	2,233			2,233
	5.65% notes due 2042 (5.65% 2042 Notes)	1,245			1,245
	5.375% notes due 2043 (5.375% 2043 Notes)	1,000			1,000
	Other notes	100			100
	Total debt	30,341			30,715
	Less current portion	(500		)	(500		)
	Total noncurrent debt	$	29,841		$	30,215

Stockholders_equity_Tables

Stockholders' equity (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Share repurchase program activity	Activity under our stock repurchase program was as follows (in millions):
		2015							2014
		Shares			Dollars				Shares			Dollars
	First quarter	2.9			$	451			—			$	—
Components of accumulated other comprehensive income	The components of accumulated other comprehensive income (AOCI) were as follows (in millions):
		Foreign				Cash flow				Available-for-sale				Other			AOCI
		currency				hedges				securities
		translation
	Balance as of December 31, 2014	$	(264	)		$	290			$	(19	)		$	(15	)	$	(8	)
	Foreign currency translation adjustments	(184		)		—				—				—			(184		)
	Unrealized gains	—				168				188				—			356
	Reclassification adjustments to income	—				114				35				—			149
	Income taxes	11				(104		)		(83		)		—			(176		)
	Balance as of March 31, 2015	$	(437	)		$	468			$	121			$	(15	)	$	137
Reclassifications out of accumulated other comprehensive income	The reclassifications out of AOCI to earnings were as follows (in millions):
			Amounts reclassified out of AOCI
	Components of AOCI		Three months ended March 31, 2015				Three months ended March 31, 2014				Line item affected in the Statements of Income
	Cash flow hedges:
	Foreign currency contract gains		$	69			$	—			Product sales
	Cross-currency swap contract (losses) gains		(183		)		14				Interest and other income, net
			(114		)		14				Total before income tax
			41				(5		)		Tax benefit/(expense)
			$	(73	)		$	9			Net of taxes
	Available-for-sale securities:
	Net realized (losses) gains		$	(35	)		$	2			Interest and other income, net
			13				(1		)		Tax benefit/(expense)
			$	(22	)		$	1			Net of taxes

Fair_value_measurement_Tables

Fair value measurement (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis	The fair value of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis was as follows (in millions):
			Quoted prices in			Significant		Significant
			active markets for			other observable		unobservable
	Fair value measurement		identical assets			inputs		inputs
	as of March 31, 2015, using:		(Level 1)			(Level 2)		(Level 3)		Total
	Assets:
	Available-for-sale investments:
	U.S. Treasury securities		$	3,284		$	—	$	—	$	3,284
	Other government-related debt securities:
	U.S.		—			518		—		518
	Foreign and other		—			1,725		—		1,725
	Corporate debt securities:
	Financial		—			6,576		—		6,576
	Industrial		—			6,902		—		6,902
	Other		—			678		—		678
	Residential mortgage-backed securities		—			1,604		—		1,604
	Other mortgage- and asset-backed securities		—			1,674		—		1,674
	Money market mutual funds		2,035			—		—		2,035
	Other short-term interest-bearing securities		—			1,520		—		1,520
	Equity securities		158			—		—		158
	Derivatives:
	Foreign currency contracts		—			679		—		679
	Interest rate swap contracts		—			109		—		109
	Total assets		$	5,477		$	21,985	$	—	$	27,462
	Liabilities:
	Derivatives:
	Foreign currency contracts		$	—		$	12	$	—	$	12
	Cross-currency swap contracts		—			197		—		197
	Contingent consideration obligations in connection with business combinations		—			—		215		215
	Total liabilities		$	—		$	209	$	215	$	424
			Quoted prices in			Significant		Significant
			active markets for			other observable		unobservable
	Fair value measurement		identical assets			inputs		inputs
	as of December 31, 2014, using:		(Level 1)			(Level 2)		(Level 3)		Total
	Assets:
	Available-for-sale investments:
	U.S. Treasury securities		$	3,646		$	—	$	—	$	3,646
	Other government-related debt securities:
	U.S.		—			528		—		528
	Foreign and other		—			1,569		—		1,569
	Corporate debt securities:
	Financial		—			6,041		—		6,041
	Industrial		—			6,351		—		6,351
	Other		—			649		—		649
	Residential mortgage-backed securities		—			1,702		—		1,702
	Other mortgage- and asset-backed securities		—			1,796		—		1,796
	Money market mutual funds		3,004			—		—		3,004
	Other short-term interest-bearing securities		—			1,302		—		1,302
	Equity securities		144			—		—		144
	Derivatives:
	Foreign currency contracts		—			360		—		360
	Cross-currency swap contracts		—			32		—		32
	Interest rate swap contracts		—			46		—		46
	Total assets		$	6,794		$	20,376	$	—	$	27,170
	Liabilities:
	Derivatives:
	Foreign currency contracts		$	—		$	4	$	—	$	4
	Cross-currency swap contracts		—			12		—		12
	Interest rate swap contracts		—			26		—		26
	Contingent consideration obligations in connection with business combinations		—			—		215		215
	Total liabilities		$	—		$	42	$	215	$	257
Changes in carrying amounts of contingent consideration obligations	The changes in carrying amounts of contingent consideration obligations were as follows (in millions):
		Three months ended March 31,
		2015			2014
	Beginning balance	$	215		$	595
	Net changes in valuation	—			1
	Ending balance	$	215		$	596

Derivative_instruments_Tables

Derivative instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of notional amounts and interest rates for cross-currency swaps	The notional amounts and interest rates of our cross-currency swaps are as follows (notional amounts in millions):
		Foreign currency							U.S. dollars
	Hedged notes	Notional amount				Interest rate			Notional amount			Interest rate
	2.125% 2019 euro Notes	€	675			2.125	%		$	864		2.6	%
	5.50% 2026 pound sterling Notes	£	475			5.5	%		$	747		6	%
	4.00% 2029 pound sterling Notes	£	700			4	%		$	1,111		4.5	%
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges	The effective portions of the unrealized gain/(loss) recognized in other comprehensive income for our derivative instruments designated as cash flow hedges were as follows (in millions):
		Three months ended
		March 31,
	Derivatives in cash flow hedging relationships	2015				2014
	Foreign currency contracts	$	392			$	13
	Cross-currency swap contracts	(224		)		4
	Total	$	168			$	17
Location in the Condensed Consolidated Statements of Income and the effective portion of gain (loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges	The locations in the Condensed Consolidated Statements of Income and the effective portions of the gain/(loss) reclassified out of AOCI into earnings for our derivative instruments designated as cash flow hedges were as follows (in millions):
				Three months ended
				March 31,
	Derivatives in cash flow hedging relationships	Statements of Income location		2015				2014
	Foreign currency contracts	Product sales		$	69			$	—
	Cross-currency swap contracts	Interest and other income, net		(183		)		14
	Total			$	(114	)		$	14
Location in the Condensed Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for the derivative instruments not designated as hedging instruments	The location in the Condensed Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for our derivative instruments not designated as hedging instruments were as follows (in millions):
				Three months ended
				March 31,
	Derivatives not designated as hedging instruments	Statements of Income location		2015				2014
	Foreign currency contracts	Interest and other income, net		$	(29	)		$	2
Fair values of derivatives included in the Condensed Consolidated Balance Sheets	The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):
		Derivative assets						Derivative liabilities
	31-Mar-15	Balance Sheet location		Fair value				Balance Sheet location		Fair value
	Derivatives designated as hedging instruments:
	Cross-currency swap contracts	Other current assets/ Other noncurrent assets		$	—			Accrued liabilities/ Other noncurrent liabilities		$	197
	Foreign currency contracts	Other current assets/ Other noncurrent assets		667				Accrued liabilities/ Other noncurrent liabilities		—
	Interest rate swap contracts	Other current assets/ Other noncurrent assets		109				Accrued liabilities/ Other noncurrent liabilities		—
	Total derivatives designated as hedging instruments			776						197
	Derivatives not designated as hedging instruments:
	Foreign currency contracts	Other current assets		12				Accrued liabilities		12
	Total derivatives not designated as hedging instruments			12						12
	Total derivatives			$	788					$	209
		Derivative assets						Derivative liabilities
	31-Dec-14	Balance Sheet location		Fair value				Balance Sheet location		Fair value
	Derivatives designated as hedging instruments:
	Cross-currency swap contracts	Other current assets/ Other noncurrent assets		$	32			Accrued liabilities/ Other noncurrent liabilities		$	12
	Foreign currency contracts	Other current assets/ Other noncurrent assets		356				Accrued liabilities/ Other noncurrent liabilities		—
	Interest rate swap contracts	Other current assets/ Other noncurrent assets		46				Accrued liabilities/ Other noncurrent liabilities		26
	Total derivatives designated as hedging instruments			434						38
	Derivatives not designated as hedging instruments:
	Foreign currency contracts	Other current assets		4				Accrued liabilities		4
	Total derivatives not designated as hedging instruments			4						4
	Total derivatives			$	438					$	42

Summary_of_significant_account2

Summary of significant accounting policies (Details) (USD $)	3 Months Ended
In Billions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
	segment
Accounting Policies [Abstract]
Number of operating segments	1
Accumulated depreciation and amortization on property, plant and equipment	$7.20	$7

Restructuring_Details_Textual

Restructuring (Details Textual) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$92	$650
Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Reduction in the number of staff by end of 2015	3,500
Expected pre-tax accounting charges	935	935
Separation costs	535	535
Accelerated depreciation and asset impairment and other related charges	400
Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Reduction in the number of staff by end of 2015	4,000
Expected pre-tax accounting charges	1,035	1,035
Separation costs	585	585
Accelerated depreciation and asset impairment and other related charges	$450

Restructuring_Summary_of_Charg

Restructuring (Summary of Charges by Type) (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2015
Restructuring Cost and Reserve [Line Items]
Separation costs	$48
Asset impairments	0
Accelerated depreciation	28
Other	16
Total	92	650
Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Separation costs	0
Asset impairments	0
Accelerated depreciation	13
Other	1
Total	14
Research and Development [Member]
Restructuring Cost and Reserve [Line Items]
Separation costs	0
Asset impairments	0
Accelerated depreciation	14
Other	3
Total	17
Selling, General and Administrative [Member]
Restructuring Cost and Reserve [Line Items]
Separation costs	0
Asset impairments	0
Accelerated depreciation	1
Other	3
Total	4
Other [Member]
Restructuring Cost and Reserve [Line Items]
Separation costs	48
Asset impairments	0
Accelerated depreciation	0
Other	9
Total	$57

Restructuring_Summary_of_Expen

Restructuring (Summary of Expenses and Payments) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Restructuring Liabilities [Roll Forward]
Restructuring liabilities as of beginning of period	$244
Expense	57
Payments	-109
Restructuring liabilities as of end of period	192
Separation Costs [Member]
Restructuring Liabilities [Roll Forward]
Restructuring liabilities as of beginning of period	221
Expense	48
Payments	-99
Restructuring liabilities as of end of period	170
Other [Member]
Restructuring Liabilities [Roll Forward]
Restructuring liabilities as of beginning of period	23
Expense	9
Payments	-10
Restructuring liabilities as of end of period	$22

Income_taxes_Details

Income taxes (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income taxes (Textual) [Abstract]
Effective income tax rate	13.50%	10.90%
Increase in gross amount of unrecognized tax benefits for period	$100
State and Local Jurisdiction [Member]
Income taxes (Textual) [Abstract]
Decrease in unrecognized tax benefits resulting from settlements with taxing authorities	$70
Puerto Rico Excise Tax [Member]
Puerto Rico Excise Tax Rate [Line Items]
Excise tax rate effective July 1, 2013 through 2017	4.00%

Earnings_per_share_Details

Earnings per share (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income (Numerator):
Net income for basic and diluted EPS	$1,623	$1,073
Shares (Denominator):
Weighted-average shares for basic EPS	761	757
Effect of dilutive securities	9	11
Weighted-average shares for diluted EPS	770	768
Basic EPS (in usd per share)	$2.13	$1.42
Diluted EPS (in usd per share)	$2.11	$1.40

Availableforsale_investments_D

Available-for-sale investments (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	$26,482	$26,763
Gross unrealized gains	280	143
Gross unrealized losses	-88	-174
Estimated fair value	26,674	26,732
U.S. Treasury securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	3,246	3,632
Gross unrealized gains	39	22
Gross unrealized losses	-1	-8
Estimated fair value	3,284	3,646
Other government-related debt securities - U.S. [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	516	530
Gross unrealized gains	2	1
Gross unrealized losses	0	-3
Estimated fair value	518	528
Other government-related debt securities - Foreign and other [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	1,690	1,572
Gross unrealized gains	41	21
Gross unrealized losses	-6	-24
Estimated fair value	1,725	1,569
Corporate debt securities - Financial [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	6,525	6,036
Gross unrealized gains	56	21
Gross unrealized losses	-5	-16
Estimated fair value	6,576	6,041
Corporate debt securities - Industrial [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	6,872	6,394
Gross unrealized gains	60	23
Gross unrealized losses	-30	-66
Estimated fair value	6,902	6,351
Corporate debt securities - Other [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	672	650
Gross unrealized gains	7	3
Gross unrealized losses	-1	-4
Estimated fair value	678	649
Residential mortgage-backed securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	1,600	1,708
Gross unrealized gains	10	4
Gross unrealized losses	-6	-10
Estimated fair value	1,604	1,702
Other mortgage- and asset-backed securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	1,708	1,837
Gross unrealized gains	3	0
Gross unrealized losses	-37	-41
Estimated fair value	1,674	1,796
Money market mutual funds [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	2,035	3,004
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Estimated fair value	2,035	3,004
Other short-term interest-bearing securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	1,520	1,302
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Estimated fair value	1,520	1,302
Total interest-bearing securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	26,384	26,665
Gross unrealized gains	218	95
Gross unrealized losses	-86	-172
Estimated fair value	26,516	26,588
Equity securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	98	98
Gross unrealized gains	62	48
Gross unrealized losses	-2	-2
Estimated fair value	$158	$144

Availableforsale_investments_F

Available-for-sale investments (Fair Values by Classification) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	$2,864	$3,731	$3,687	$3,805
Marketable securities	24,254	23,295
Other assets — noncurrent	1,779	1,592
Total available-for-sale investments	26,674	26,732
Available-for-sale investments [Member]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	2,262	3,293
Other assets — noncurrent	$158	$144

Availableforsale_investments_F1

Available-for-sale investments (Fair Values by Contractual Maturity) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Fair values of available-for-sale debt security investments by contractual maturity
Maturing in one year or less	$4,015	$4,936
Maturing after one year through three years	7,428	6,829
Maturing after three years through five years	8,146	7,840
Maturing after five years through ten years	3,471	3,267
Maturing after ten years	178	218
Mortgage- and asset-backed securities	3,278	3,498
Total available-for-sale investments	26,674	26,732
Total interest-bearing securities [Member]
Fair values of available-for-sale debt security investments by contractual maturity
Total available-for-sale investments	$26,516	$26,588

Availableforsale_investments_U

Available-for-sale investments (Unrealized Losses and Fair Values) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	$4,995	$11,569
Less than 12 months, Unrealized losses	-49	-115
12 months or greater, Fair value	1,104	1,867
12 months or greater, Unrealized losses	-39	-59
U.S. Treasury securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	635	1,770
Less than 12 months, Unrealized losses	-1	-7
12 months or greater, Fair value	30	171
12 months or greater, Unrealized losses	0	-1
Other government-related debt securities - U.S. [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	86	160
Less than 12 months, Unrealized losses	0	0
12 months or greater, Fair value	35	178
12 months or greater, Unrealized losses	0	-3
Other government-related debt securities - Foreign and other [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	281	514
Less than 12 months, Unrealized losses	-4	-14
12 months or greater, Fair value	71	159
12 months or greater, Unrealized losses	-2	-10
Corporate debt securities - Financial [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	859	3,150
Less than 12 months, Unrealized losses	-4	-14
12 months or greater, Fair value	65	158
12 months or greater, Unrealized losses	-1	-2
Corporate debt securities - Industrial [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	2,188	3,931
Less than 12 months, Unrealized losses	-27	-62
12 months or greater, Fair value	170	222
12 months or greater, Unrealized losses	-2	-4
Corporate debt securities - Other [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	159	354
Less than 12 months, Unrealized losses	-2	-4
12 months or greater, Fair value	0	5
12 months or greater, Unrealized losses	0	0
Residential mortgage-backed securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	320	614
Less than 12 months, Unrealized losses	-2	-4
12 months or greater, Fair value	277	413
12 months or greater, Unrealized losses	-4	-6
Other mortgage- and asset-backed securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	462	1,071
Less than 12 months, Unrealized losses	-7	-8
12 months or greater, Fair value	456	561
12 months or greater, Unrealized losses	-30	-33
Equity securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	5	5
Less than 12 months, Unrealized losses	-2	-2
12 months or greater, Fair value	0	0
12 months or greater, Unrealized losses	$0	$0

Availableforsale_investments_D1

Available-for-sale investments (Details Textual) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Investments [Line Items]
Total realized gains	$36	$28
Total realized losses	71	26
Available-for-sale investments [Member]
Investments [Line Items]
Cash and cash equivalents	$602		$438

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Inventories
Raw materials	$212	$198
Work in process	1,282	1,551
Finished goods	1,192	898
Total inventories	$2,686	$2,647

Goodwill_and_other_intangible_2

Goodwill and other intangible assets (Goodwill Roll Forward) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014
Goodwill [Roll Forward]
Beginning balance	$14,788		$14,968
Goodwill related to acquisitions of businesses	0	[1]	-130	[1]
Currency translation and other adjustments	-67		-6
Ending balance	$14,721		$14,832
[1]	Composed of goodwill recognized on the acquisition dates of business combinations and subsequent adjustments to these amounts resulting from changes to the acquisition date fair values of net assets acquired in the business combinations recorded during their respective measurement periods.

Goodwill_and_other_intangible_3

Goodwill and other intangible assets (Idenfitiable Intangible Assets) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
Gross carrying amount	$18,517	$18,625
Accumulated amortization	-6,252	-5,932
Intangible assets, net	12,265	12,693
Finite-lived intangible assets:
Gross carrying amount	16,377	16,470
Accumulated amortization	-6,252	-5,932
Intangible assets, net	10,125	10,538
In-process Research and Development (IPR&D) [Member]
Indefinite-lived intangible assets:
Indefinite-lived intangible assets	2,140	2,155
Developed Product Technology Rights [Member]
Finite-lived intangible assets:
Gross carrying amount	10,786	10,826
Accumulated amortization	-4,361	-4,155
Intangible assets, net	6,425	6,671
Licensing Rights [Member]
Finite-lived intangible assets:
Gross carrying amount	3,232	3,236
Accumulated amortization	-770	-696
Intangible assets, net	2,462	2,540
R&D Technology Rights [Member]
Finite-lived intangible assets:
Gross carrying amount	1,136	1,167
Accumulated amortization	-577	-569
Intangible assets, net	559	598
Marketing-related Rights [Member]
Finite-lived intangible assets:
Gross carrying amount	1,223	1,241
Accumulated amortization	-544	-512
Intangible assets, net	$679	$729

Goodwill_and_other_intangible_4

Goodwill and other intangible assets (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Amortization charges associated with finite-lived intangible assets	$341,000,000	$357,000,000
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Total estimated amortization of finite- lived intangible assets for the nine months ending 2015	1,000,000,000
Total estimated amortization of finite- lived intangible assets for 2016	1,300,000,000
Total estimated amortization of finite- lived intangible assets for 2017	1,200,000,000
Total estimated amortization of finite- lived intangible assets for 2018	1,000,000,000
Total estimated amortization of finite- lived intangible assets for 2019	939,000,000
Total estimated amortization of finite- lived intangible assets for 2020	891,000,000
IPR&D - Talimogene Laherparepvec [Member]
Indefinite-lived Intangible Assets [Line Items]
Carrying value	$675,000,000

Financing_arrangements_Details

Financing arrangements (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Carrying values of long-term borrowings
Other notes	$100	$100
Total debt	30,341	30,715
Less current portion	-500	-500
Total noncurrent debt	29,841	30,215
2.30% notes due 2016 (2.30% 2016 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	750	749
Interest rate, stated percentage	2.30%	2.30%
2.50% notes due 2016 (2.50% 2016 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	1,000	1,000
Interest rate, stated percentage	2.50%	2.50%
Floating Rate Notes due 2017 [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	600	600
1.25% notes due 2017 (1.25% 2017 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	849	849
Interest rate, stated percentage	1.25%	1.25%
2.125% notes due 2017 (2.125% 2017 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	1,249	1,249
Interest rate, stated percentage	2.13%	2.13%
5.85% notes due 2017 (5.85% 2017 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	1,100	1,100
Interest rate, stated percentage	5.85%	5.85%
6.15% notes due 2018 (6.15% 2018 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	500	500
Interest rate, stated percentage	6.15%	6.15%
Term Loan Due 2018 [Member]
Carrying values of long-term borrowings
Loans payable to bank	4,250	4,375
Term Loan Credit Facility, repayment of principal	125
4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	599	668
Interest rate, stated percentage	4.38%	4.38%
Floating Rate Notes due 2019 [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	250	250
2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	1,398	1,398
Interest rate, stated percentage	2.20%	2.20%
5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	999	999
Interest rate, stated percentage	5.70%	5.70%
2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	722	814
Interest rate, stated percentage	2.13%	2.13%
4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	300	300
Interest rate, stated percentage	4.50%	4.50%
3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	898	898
Interest rate, stated percentage	3.45%	3.45%
4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	998	998
Interest rate, stated percentage	4.10%	4.10%
3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	1,747	1,747
Interest rate, stated percentage	3.88%	3.88%
3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	747	747
Interest rate, stated percentage	3.63%	3.63%
3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	1,398	1,398
Interest rate, stated percentage	3.63%	3.63%
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	699	735
Interest rate, stated percentage	5.50%	5.50%
4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	1,023	1,076
Interest rate, stated percentage	4.00%	4.00%
6.375% notes due 2037 (6.375% 2037 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	899	899
Interest rate, stated percentage	6.38%	6.38%
6.90% notes due 2038 (6.90% 2038 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	499	499
Interest rate, stated percentage	6.90%	6.90%
6.40% notes due 2039 (6.40% 2039 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	996	996
Interest rate, stated percentage	6.40%	6.40%
5.75% notes due 2040 (5.75% 2040 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	697	697
Interest rate, stated percentage	5.75%	5.75%
4.95% notes due 2041 (4.95% 2041 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	596	596
Interest rate, stated percentage	4.95%	4.95%
5.15% notes due 2041 (5.15% 2041 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	2,233	2,233
Interest rate, stated percentage	5.15%	5.15%
5.65% notes due 2042 (5.65% 2042 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	1,245	1,245
Interest rate, stated percentage	5.65%	5.65%
5.375% notes due 2043 (5.375% 2043 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent	$1,000	$1,000
Interest rate, stated percentage	5.38%	5.38%

Stockholders_equity_Details_Te

Stockholders' equity (Details Textual) (USD $)	0 Months Ended			3 Months Ended
In Billions, except Per Share data, unless otherwise specified	Mar. 06, 2015	Mar. 04, 2015	Dec. 17, 2014	Mar. 31, 2015	Mar. 31, 2014
Equity [Abstract]
Amount available for stock repurchases under a board approved stock repurchase plan				$3.40
Common stock, dividends declared per share (in usd per share)		$0.79	$0.79
Dividends paid per share (in usd per share)	$0.79			$0.79	$0.61

Stockholders_equity_Share_Repu

Stockholders' equity (Share Repurchase Program) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Equity [Abstract]
Stock repurchased, Shares	2.9	0
Stock repurchased	$451	$0

Stockholders_equity_Components

Stockholders' equity (Components of AOCI) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, Foreign currency translation	($264)
Beginning balance, Cash flow hedges	290
Beginning balance, Available-for-sale securities	-19
Beginning balance, Other	-15
Beginning balance, AOCI	-8
Other Comprehensive Income (Loss), before Tax [Abstract]
Foreign currency translation adjustments	-184
Unrealized gains (losses), Cash flow hedges	168
Unrealized gains (losses), Available-for-sale securities	188
Unrealized gains (losses), Other	0
Unrealized gains (losses), AOCI	356
Reclassification adjustments to income, Cash flow hedges	114
Reclassification adjustments to income, Available-for-sale securities	35
Reclassification adjustments to income, AOCI	149
Income taxes, Foreign currency translation	11
Income taxes, Cash flow hedges	-104
Income taxes, Available-for-sale securities	-83
Income taxes, Other	0
Income taxes, AOCI	-176
Ending balance, Foreign currency translation	-437
Ending balance, Cash flow hedges	468
Ending balance, Available-for-sale securities	121
Ending balance, Other	-15
Ending balance, AOCI	$137

Stockholders_equity_Relcassifi

Stockholders' equity (Relcassifications out of AOCI) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	$4,874	$4,356
Interest and other income, net	106	99
Income before income taxes	1,876	1,204
Tax benefit/(expense)	-253	-131
Net income	1,623	1,073
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash Flow Hedges [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	69	0
Interest and other income, net	-183	14
Income before income taxes	-114	14
Tax benefit/(expense)	41	-5
Net income	-73	9
Reclassification out of Accumulated Other Comprehensive Income [Member] | Realized Gains and Losses on Available-for-sale Securities [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	-35	2
Tax benefit/(expense)	13	-1
Net income	($22)	$1

Fair_value_measurement_Details

Fair value measurement (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Assets:
Total available-for-sale investments	$26,674	$26,732
Fair Value, Measurements, Recurring [Member]
Derivative Assets:
Interest rate swap contracts	109	46
Total assets	27,462	27,170
Derivative Liabilities:
Interest rate swap contracts		26
Contingent consideration obligations in connection with business combinations	215	215
Total liabilities	424	257
Fair Value, Measurements, Recurring [Member] | Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	679	360
Derivative Liabilities:
Foreign currency contracts	12	4
Fair Value, Measurements, Recurring [Member] | Cross currency swap contracts [Member]
Derivative Assets:
Foreign currency contracts		32
Derivative Liabilities:
Foreign currency contracts	197	12
Fair Value, Measurements, Recurring [Member] | U.S. Treasury securities [Member]
Assets:
Total available-for-sale investments	3,284	3,646
Fair Value, Measurements, Recurring [Member] | Other government-related debt securities - U.S. [Member]
Assets:
Total available-for-sale investments	518	528
Fair Value, Measurements, Recurring [Member] | Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	1,725	1,569
Fair Value, Measurements, Recurring [Member] | Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	6,576	6,041
Fair Value, Measurements, Recurring [Member] | Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	6,902	6,351
Fair Value, Measurements, Recurring [Member] | Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	678	649
Fair Value, Measurements, Recurring [Member] | Residential mortgage-backed securities [Member]
Assets:
Total available-for-sale investments	1,604	1,702
Fair Value, Measurements, Recurring [Member] | Other mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	1,674	1,796
Fair Value, Measurements, Recurring [Member] | Money market mutual funds [Member]
Assets:
Total available-for-sale investments	2,035	3,004
Fair Value, Measurements, Recurring [Member] | Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments	1,520	1,302
Fair Value, Measurements, Recurring [Member] | Equity securities [Member]
Assets:
Total available-for-sale investments	158	144
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member]
Derivative Assets:
Interest rate swap contracts	0	0
Total assets	5,477	6,794
Derivative Liabilities:
Interest rate swap contracts		0
Contingent consideration obligations in connection with business combinations	0	0
Total liabilities	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	0	0
Derivative Liabilities:
Foreign currency contracts	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Cross currency swap contracts [Member]
Derivative Assets:
Foreign currency contracts		0
Derivative Liabilities:
Foreign currency contracts	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | U.S. Treasury securities [Member]
Assets:
Total available-for-sale investments	3,284	3,646
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Other government-related debt securities - U.S. [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Residential mortgage-backed securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Other mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Money market mutual funds [Member]
Assets:
Total available-for-sale investments	2,035	3,004
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Quoted prices in active markets for identical assets (Level 1) [Member] | Equity securities [Member]
Assets:
Total available-for-sale investments	158	144
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member]
Derivative Assets:
Interest rate swap contracts	109	46
Total assets	21,985	20,376
Derivative Liabilities:
Interest rate swap contracts		26
Contingent consideration obligations in connection with business combinations	0	0
Total liabilities	209	42
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	679	360
Derivative Liabilities:
Foreign currency contracts	12	4
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Cross currency swap contracts [Member]
Derivative Assets:
Foreign currency contracts		32
Derivative Liabilities:
Foreign currency contracts	197	12
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | U.S. Treasury securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Other government-related debt securities - U.S. [Member]
Assets:
Total available-for-sale investments	518	528
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	1,725	1,569
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	6,576	6,041
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	6,902	6,351
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	678	649
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Residential mortgage-backed securities [Member]
Assets:
Total available-for-sale investments	1,604	1,702
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Other mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	1,674	1,796
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Money market mutual funds [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments	1,520	1,302
Fair Value, Measurements, Recurring [Member] | Significant other observable inputs (Level 2) [Member] | Equity securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member]
Derivative Assets:
Interest rate swap contracts	0	0
Total assets	0	0
Derivative Liabilities:
Interest rate swap contracts		0
Contingent consideration obligations in connection with business combinations	215	215	596	595
Total liabilities	215	215
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	0	0
Derivative Liabilities:
Foreign currency contracts	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Cross currency swap contracts [Member]
Derivative Assets:
Foreign currency contracts		0
Derivative Liabilities:
Foreign currency contracts	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | U.S. Treasury securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Other government-related debt securities - U.S. [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Residential mortgage-backed securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Other mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Money market mutual funds [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] | Significant unobservable inputs (Level 3) [Member] | Equity securities [Member]
Assets:
Total available-for-sale investments	$0	$0

Fair_value_measurement_Changes

Fair value measurement (Changes in Contingent Consideration Obligation) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Business Combination, Contingent Consideration [Roll Forward]
Beginning balance			$215
Ending balance	215		215
Significant unobservable inputs (Level 3) [Member]
Business Combination, Contingent Consideration [Roll Forward]
Beginning balance	215	595
Net changes in valuation	0	1
Ending balance	$215	$596

Fair_value_measurements_Detail

Fair value measurements (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Mar. 31, 2011
Business Acquisition [Line Items]
Length of time hedged in foreign currency contracts	3 years
Payment of contingent consideration obligation	$225,000,000	$0
Fair Value Measurement (Textual) [Abstract]
Aggregate fair value of long-term debt, including current portion	33,500,000,000		33,600,000,000
Carrying value of long-term debt, including current portion	30,341,000,000		30,715,000,000
BioVex Group Inc [Member]
Business Acquisition [Line Items]
Maximum additional consideration due contingent on milestones				575,000,000
BioVex Group Inc [Member] | Due to Filing of BLA in the US [Member]
Business Acquisition [Line Items]
Payment of contingent consideration obligation			125,000,000
BioVex Group Inc [Member] | Upon First Commercial Sale in the US [Member]
Business Acquisition [Line Items]
Additional contingent consideration upon achievement of milestones	125,000,000
BioVex Group Inc [Member] | Upon Achievement of Agreed Level of Worldwide Sales [Member]
Business Acquisition [Line Items]
Additional contingent consideration upon achievement of milestones	125,000,000
BioVex Group Inc [Member] | Upon Achievement of Certain Other Regulatory and Sales-related Milestones [Member]
Business Acquisition [Line Items]
Additional contingent consideration upon achievement of milestones	200,000,000
Onyx Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Payment of contingent consideration obligation	225,000,000
Additional contingent consideration upon achievement of milestones	$150,000,000
Number of milestone payments	2
Other Government-related and Corporate Debt Securities [Member]
Business Acquisition [Line Items]
Investment maturity period	5 years

Derivative_instruments_Crosscu

Derivative instruments (Cross-currency Swaps) (Details) (Cash flow hedge [Member], Cross currency swap contracts [Member])

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

In Millions, unless otherwise specified

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]

USD ($)

EUR (€)

Interest rate received [Member]

Interest rate paid [Member]

USD ($)

GBP (£)

Interest rate received [Member]

Interest rate paid [Member]

USD ($)

GBP (£)

Interest rate received [Member]

Interest rate paid [Member]

Derivative [Line Items]

Notional amount

$864

€ 675

$747

£ 475

$1,111

£ 700

Interest rate

2.13%

2.60%

5.50%

6.00%

4.00%

4.50%

Derivative_instruments_Effecti

Derivative instruments (Effective Potion of Unrealized Gain (Loss)) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	$168	$17
Foreign currency contracts [Member]
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	392	13
Cross currency swap contracts [Member]
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	($224)	$4

Derivative_instruments_Locatio

Derivative instruments (Locations and Effective Potions of Gain (Loss) Reclassified out of AOCI) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Derivative Instruments Gain Loss [Line Items]
Product sales	$4,874	$4,356
Interest and other income, net	106	99
Income before income taxes	1,876	1,204
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments Gain Loss [Line Items]
Product sales	69	0
Interest and other income, net	-183	14
Income before income taxes	-114	14
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedge [Member]
Derivative Instruments Gain Loss [Line Items]
Income before income taxes	-114	14
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedge [Member] | Foreign currency contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Product sales	69	0
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Cash flow hedge [Member] | Cross currency swap contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Interest and other income, net	($183)	$14

Derivative_instruments_Locatio1

Derivative instruments (Locations and Gain (Loss) for Derivatives Not Designated as Hedging Instruments) (Details) (Foreign currency contracts [Member], Interest and other income, net [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Foreign currency contracts [Member] | Interest and other income, net [Member]
Location in the Condensed Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for our derivative instruments not designated as hedging instruments
Amount of gain (loss) recognized in interest and other income, net	($29)	$2

Derivative_instruments_Details

Derivative instruments (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Assets
Total derivative assets, fair value	$788	$438
Liabilities
Total derivative liabilities, fair value	209	42
Derivatives designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	776	434
Liabilities
Total derivative liabilities, fair value	197	38
Derivatives designated as hedging instrument [Member] | Cross currency swap contracts [Member] | Other current assets/Other noncurrent assets [Member]
Assets
Total derivative assets, fair value	0	32
Derivatives designated as hedging instrument [Member] | Cross currency swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	197	12
Derivatives designated as hedging instrument [Member] | Foreign currency contracts [Member] | Other current assets/Other noncurrent assets [Member]
Assets
Total derivative assets, fair value	667	356
Derivatives designated as hedging instrument [Member] | Foreign currency contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	0	0
Derivatives designated as hedging instrument [Member] | Interest rate swap contracts [Member] | Other current assets/Other noncurrent assets [Member]
Assets
Total derivative assets, fair value	109	46
Derivatives designated as hedging instrument [Member] | Interest rate swap contracts [Member] | Accrued liabilities/Other noncurrent liabilities [Member]
Liabilities
Total derivative liabilities, fair value	0	26
Derivatives not designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	12	4
Liabilities
Total derivative liabilities, fair value	12	4
Derivatives not designated as hedging instrument [Member] | Foreign currency contracts [Member] | Other current assets [Member]
Assets
Total derivative assets, fair value	12	4
Derivatives not designated as hedging instrument [Member] | Foreign currency contracts [Member] | Accrued liabilities [Member]
Liabilities
Total derivative liabilities, fair value	$12	$4

Derivative_instruments_Details1

Derivative instruments (Details Textual) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Derivative Instruments Gain Loss [Line Items]
Length of time hedged in foreign currency contracts	3 years
Interest expense, net [Member]
Derivative Instruments Gain Loss [Line Items]
Unrealized gain (loss) on the hedged debt	-89	($62)
Unrealized gain (loss) on interest rate swaps	89	62
Foreign currency forward contracts [Member] | Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative, notional amount	3,700		3,800
Foreign currency forward contracts [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative, notional amount	957		875
Foreign currency option contracts [Member] | Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative, notional amount	352		271
Foreign currency and cross currency swap contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Amounts expected to be reclassified from AOCI into earnings over the next 12 months	358
Forward interest rate contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Amounts expected to be reclassified from AOCI into earnings over the next 12 months	-1
Interest rate swap [Member] | Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative, notional amount	6,650		$6,650
Rate adjustment to LIBOR on interest rate swap agreements [Member] | LIBOR [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative lower range variable interest rate	0.40%
Derivative higher range variable interest rate	2.00%